ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PRVB Provention Bio Inc

24.98
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Provention Bio Inc NASDAQ:PRVB NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.98 25.04 24.90 0 01:00:00

Provention Bio to Present at Upcoming Conferences

19/02/2020 12:00pm

PR Newswire (US)


Provention Bio (NASDAQ:PRVB)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Provention Bio Charts.

OLDWICK, N.J., Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming  conferences:

(PRNewsfoto/Provention Bio, Inc.)

  • The 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020, at 10:00 am E.T. The conference is being held at the Lotte New York Palace Hotel, New York, NY.
  • The 40th Annual Cowen Health Care Conference on Monday, March 2, 2020, at 4:50 pm E.T. The conference is being held at the Boston Marriott Copley Place, Boston, MA.

Each presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. Each webcast will be archived on the Company's website for 90 days following the presentation.

About Provention Bio, Inc.

Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Provention's mission is to in-license, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), celiac disease and lupus. Provention's diversified portfolio includes advanced-stage product development candidates that have undergone clinical testing by other companies.

Investors:
Sam Martin, Argot Partners  
sam@argotpartners.com 
212-600-1902

Media:
David Rosen
david.rosen@argotpartners.com
212-600-1902

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-upcoming-conferences-301006966.html

SOURCE Provention Bio, Inc.

Copyright 2020 PR Newswire

1 Year Provention Bio Chart

1 Year Provention Bio Chart

1 Month Provention Bio Chart

1 Month Provention Bio Chart

Your Recent History

Delayed Upgrade Clock